Jodie Crawford

Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical Practice

Jørgen Vestbo, David Leather, Nawar Diar Bakerly et al. · New England Journal of Medicine · 2016 · 191 citations · Full text

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β₂agonist vilanterol administered once daily for 52 weeks in patients ≥12 years old with asthma: a randomised trial

Paul M. O’Byrne, Eugene R. Bleecker, Jan Lötvall et al. · Thorax · 2013 · 74 citations · Full text

Effectiveness <i>versus</i> efficacy trials in COPD: how study design influences outcomes and applicability

Ashley Woodcock, I. Boucot, David Leather et al. · European Respiratory Journal · 2018 · 38 citations · Full text

Asthma, Pulmonary Care, Advanced Lung Disease +18

Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: A randomized trial

Jiangtao Lin, Jian Kang, Sang Haak Lee et al. · Respiratory Medicine · 2014 · 21 citations

Asthma, Allergy, Allergy Medicine +8

Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study

Yoichi Nakamura, Soichiro Hozawa, Hironori Sagara et al. · Current Medical Research and Opinion · 2021 · 12 citations · Full text